Discounted Cash Flow (DCF) Analysis Unlevered

Renalytix Plc (RNLX)

$0.75

-0.10 (-11.67%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 0.75 | undervalue

Operating Data

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Actual
2024
Projected
2025
Projected
2026
Projected
2027
Projected
2028
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Actual
2024
Projected
2025
Projected
2026
Projected
2027
Projected
2028
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.75
Beta 1.748
Diluted Shares Outstanding 41.11
Cost of Debt
Tax Rate -0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 12.502
Total Debt 12.15
Total Equity 30.83
Total Capital 42.98
Debt Weighting 28.27
Equity Weighting 71.73
Wacc

Build Up Free Cash

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Actual
2024
Projected
2025
Projected
2026
Projected
2027
Projected
2028
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 14.71%12.82%13.35%-14.31%-0.00%5.31%5.31%5.31%5.31%5.31%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -13.05-1.31-1.63-0.69------
UFCF ----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 10.38
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -12.53
Equity Value -
Shares Outstanding 41.11
Equity Value Per Share -